Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT07492914 2026-03-25

Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma

Phase 2 Not yet recruiting

30 enrolled

Head & Neck

Head and Neck Neoplasms

NCT07367178 2026-01-28

SATROPIN

Phase 2 Not yet recruiting

30 enrolled

Breast

Breast Neoplasms

NCT07368543 2026-01-28

STORM

Phase 2 Not yet recruiting

216 enrolled

Breast

Breast Neoplasms

NCT07134556 2026-01-23

ADJUNCT

Phase 2 Not yet recruiting

25 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07299409 2025-12-23

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

Phase 2 Not yet recruiting

24 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07178730 2025-09-17

ADAPT-TN-IV

Phase 3 Not yet recruiting

765 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07163481 2025-09-16

SoGreat

Phase 1 Not yet recruiting

12 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Phase 2 Not yet recruiting

150 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07151586 2025-09-03

ALTER

Phase 2 Not yet recruiting

260 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06528483 2024-07-30

preSAVE

Phase 2 Not yet recruiting

63 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06462079 2024-06-17

Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases

Phase 2 Not yet recruiting

43 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

Clinical Trials

TianjinCIH

Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma

SATROPIN

STORM

ADJUNCT

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

ADAPT-TN-IV

SoGreat

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

ALTER

preSAVE

Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases